These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 4144250)

  • 1. Influence of anticholinergic-antiparkinsonian agents on the effects of narcoanalgesic drugs in the rat.
    Fischer E; Heller B; Lumbreras N
    Experientia; 1973 Feb; 29(2):188-9. PubMed ID: 4144250
    [No Abstract]   [Full Text] [Related]  

  • 2. Proceedings: Iontophoretic study of the central anticholinergic properties of BRL 1288.
    Clarke G; Davies J; Straughan DW
    Br J Pharmacol; 1972 Feb; 44(2):344P-345P. PubMed ID: 4668612
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of anticholinergic antiparkinsonian drugs on binding of muscarinic receptor subtypes in rat brain.
    Katayama S; Ishizaki F; Yamamura Y; Khoriyama T; Kito S
    Res Commun Chem Pathol Pharmacol; 1990 Sep; 69(3):261-70. PubMed ID: 2236897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the antiparkinsonian drug budipine on neurotransmitter release in central nervous system tissue in vitro.
    Jackisch R; Huang HY; Reimann W; Limberger N
    J Pharmacol Exp Ther; 1993 Feb; 264(2):889-98. PubMed ID: 8094757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antagonism between reserpine and some antiparkinson drugs in electroseizure.
    Jurna I; Regélhy B
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1968; 259(5):442-59. PubMed ID: 4236499
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of amantadine and of some synthetic antiparkinsonian drugs on the behavioral response to L-DOPA in mice.
    Florio V; Longo VG
    Physiol Behav; 1971 Apr; 6(4):465-6. PubMed ID: 5148760
    [No Abstract]   [Full Text] [Related]  

  • 7. The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists.
    Jackisch R; Kruchen A; Sauermann W; Hertting G; Feuerstein TJ
    Eur J Pharmacol; 1994 Oct; 264(2):207-11. PubMed ID: 7851484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of anticholinergic hallucinogens on spontaneous and conditioned behaviour in rats.
    Kabes J; Fink Z
    Act Nerv Super (Praha); 1971; 13(3):195-6. PubMed ID: 5113839
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacological study of piroheptine, a new antiparkinson drug, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-ethyl-2-methylpyrrolidine. I. Effects on drug-induced tremor and catatonia, and on adrenergic actions.
    Hitomi M; Kumadaki N; Furukawa T; Ito N; Sato Y; Kumada S
    Arzneimittelforschung; 1972 Jun; 22(6):953-61. PubMed ID: 4626187
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects.
    Grimaldi R; Perucca E; Ruberto G; Gelmi C; Trimarchi F; Hollmann M; Crema A
    Eur J Clin Pharmacol; 1986; 29(6):735-7. PubMed ID: 3709619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of amphetamine induced stereotyped behaviour as a model for the experimental evaluation of antiparkinson agents.
    Costall B; Naylor RJ; Wright T
    Arzneimittelforschung; 1972 Jul; 22(7):1178-83. PubMed ID: 4404343
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of anti-parkinsonism drugs on gastric emptying and intestinal transit in the rat.
    Feldman S; Putcha L
    Pharmacology; 1977; 15(6):503-11. PubMed ID: 22880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reserpine rigidity in the rat--a model for the analysis of antiparkinson drugs.
    Jurna I
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1968; 259(2):181. PubMed ID: 4232669
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparison of the inhibitory effects of certain antiparkinsonian agents on dopamine accumulation into the rat striatum.
    Nose T; Segawa T
    Jpn J Pharmacol; 1974 Apr; 24(2):299-305. PubMed ID: 4152745
    [No Abstract]   [Full Text] [Related]  

  • 15. Drugs for Parkinson's disease reduce tremor induced by physostigmine.
    Gothóni P; Lehtinen M; Fincke M
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Jul; 323(3):205-10. PubMed ID: 6621715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of anti-Parkinsonian drugs on haloperidol-induced inhibition of the conditioned-avoidance response in rats.
    Davies JA; Jackson B; Redfern PH
    Neuropharmacology; 1973 Aug; 12(8):735-40. PubMed ID: 4746439
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of the antiparkinsonian drug budipine on central neurotransmitter systems.
    Klockgether T; Wüllner U; Steinbach JP; Petersen V; Turski L; Löschmann PA
    Eur J Pharmacol; 1996 Apr; 301(1-3):67-73. PubMed ID: 8773448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of physostigmine and tetrabenazine on spinal motor control and its inhibition by drugs which influence reserpine rigidity.
    Jurna I; Theres C; Bachmann T
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1969; 263(3):427-38. PubMed ID: 4239718
    [No Abstract]   [Full Text] [Related]  

  • 19. The effects of parachlorophenylalanine on nontolerant rats and of cholinergic blocking drugs on toleaant rats to morphine.
    Oka T; Nozaki M
    Jpn J Pharmacol; 1970 Sep; 20(3):455-7. PubMed ID: 5312655
    [No Abstract]   [Full Text] [Related]  

  • 20. [Modification of central mechanisms of action by anticholinergics].
    Haas H; Jantos W
    Arzneimittelforschung; 1969 Jan; 19(1):54-62. PubMed ID: 5819363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.